{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:09:06Z","timestamp":1761865746542,"version":"build-2065373602"},"reference-count":23,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2008,7,30]],"date-time":"2008-07-30T00:00:00Z","timestamp":1217376000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Diabetes Obesity Metabolism"],"published-print":{"date-parts":[[2009,3]]},"abstract":"<jats:p>\n                    <jats:bold>Objective:\u2002<\/jats:bold>\n                    To explore vital sign changes among patient subgroups during the 6\u2010week lead\u2010in period of the sibutramine cardiovascular outcomes (SCOUT) trial.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    SCOUT is an ongoing, double\u2010blind, randomized, placebo\u2010controlled outcome trial in overweight\/obese patients at high risk of a cardiovascular event. During the 6\u2010week lead\u2010in period, 10\u2003742 patients received sibutramine and weight management. Vital sign changes were assessed\n                    <jats:italic>post hoc<\/jats:italic>\n                    by initial blood pressure (mmHg) categorized as normal (&lt;130\/&lt;85), high\u2010normal (130 to &lt;140\/85 to &lt;90) or hypertensive (\u2265140\/\u226590); weight change categories (weight gain\/no weight change, &gt;0 to 2.5% weight loss, &gt;2.5 to 5% weight loss and &gt;5% weight loss) and current antihypertensive medication class use (none, one, or two or more). To assess the impact of sibutramine on blood pressure and pulse rate, only patients (N\u2003=\u200310\u2003025) who reported no change in the class of antihypertensive medication used and who did not report an increase in antihypertensive medication use were analysed.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    At entry, approximately 50% of patients were hypertensive and 26% were high\u2010normal. In hypertensive patients, blood pressure changes (mmHg) decreased by median [5th, 95th percentile] of \u22126.5 systolic [\u221227.0, 8.0] and \u22122.0 diastolic [\u221215.0, 8.0] (p\u2003&lt;\u20030.001). Hypertensive patients with no weight loss or with weight gain had median decreases of \u22123.5 systolic [\u221226.0, 10.0] and \u22121.5 diastolic [\u221216.0, 9.0] (p\u2003&lt;\u20030.001). Normotensive patients had median increases of 1.5 systolic [\u221215.0, 19.5] and 1.0 diastolic [\u221210.5, 13.0] (p\u2003&lt;\u20030.001) attenuated with increasing weight loss. Approximately 43% of patients initially categorized as hypertensive had a lower blood pressure category at end\u2010point. Concomitant antihypertensive medication classes did not affect blood pressure reductions. Pulse rates were uniformly elevated (median 1\u20134\u2003bpm, p\u2003&lt;\u20030.001) across blood pressure and weight change categories.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusions:\u2002<\/jats:bold>\n                    In hypertensive patients (\u2265140\/\u226590), blood pressure decreases were observed during 6\u2010week treatment with sibutramine even when body weight was unchanged. In patients with normal blood pressure (&lt;130\/&lt;85), weight loss of &gt;5% induced decreases in systolic blood pressure; otherwise, small increases were observed. Small pulse rate increases were observed regardless of blood pressure or weight change status.\n                  <\/jats:p>","DOI":"10.1111\/j.1463-1326.2008.00930.x","type":"journal-article","created":{"date-parts":[[2008,7,30]],"date-time":"2008-07-30T09:30:37Z","timestamp":1217410237000},"page":"239-250","source":"Crossref","is-referenced-by-count":23,"title":["Blood pressure changes associated with sibutramine and weight management \u2013 an analysis from the 6\u2010week lead\u2010in period of the sibutramine cardiovascular outcomes trial (SCOUT)*"],"prefix":"10.1111","volume":"11","author":[{"given":"A. M.","family":"Sharma","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"I. D.","family":"Caterson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.","family":"Coutinho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.","family":"Finer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Van Gaal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A. P.","family":"Maggioni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Torp\u2010Pedersen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. P.","family":"Bacher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. M.","family":"Shepherd","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W. P. T.","family":"James","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"SCOUT Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2009,1,27]]},"reference":[{"key":"e_1_2_8_2_2","unstructured":"International Obesity TaskForce Prevalence Data. Available from URL:http:\/\/www.iotf.org\/database\/index.asp. Accessed 10 Dec 2007."},{"issue":"2","key":"e_1_2_8_3_2","first-page":"51S","article-title":"Clinical guidelines on the identification, evaluation, and treatment of overweight and obesity in adults \u2013 the evidence report","volume":"6","author":"National Institutes of Health","year":"1998","journal-title":"Obes Res"},{"key":"e_1_2_8_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.04.016"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-147-1-200707030-00007"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1503\/cmaj.061409"},{"key":"e_1_2_8_7_2","unstructured":"National Institute for Health and Clinical Excellence.Clinical Guideline 43 (CG 43). Obesity: the prevention identification assessment and management of overweight and obesity in adults and children.December 2006.http:\/\/www.nice.org.uk\/nicemedia\/pdf\/CG43NICEGuideline.pdf.pg.53. Accessed June 2008."},{"key":"e_1_2_8_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(07)60033-6"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(00)03491-7"},{"key":"e_1_2_8_10_2","doi-asserted-by":"publisher","DOI":"10.2337\/diacare.26.1.125"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802218"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000036370.31856.73"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1038\/sj.ijo.0802887"},{"key":"e_1_2_8_14_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clpt.2006.02.002"},{"key":"e_1_2_8_15_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehm217"},{"key":"e_1_2_8_16_2","doi-asserted-by":"publisher","DOI":"10.1097\/HJH.0b013e3281fc975a"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.amjhyper.2006.01.019"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.0000251933.22091.24"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1097\/01.hjh.0000217838.49842.1e"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehl259"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.162.20.2313"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1161\/01.HYP.37.5.1256"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1016\/0002-8703(91)90970-S"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.106.625400"}],"container-title":["Diabetes, Obesity and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1463-1326.2008.00930.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/pdf\/10.1111\/j.1463-1326.2008.00930.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T23:05:12Z","timestamp":1761865512000},"score":1,"resource":{"primary":{"URL":"https:\/\/dom-pubs.pericles-prod.literatumonline.com\/doi\/10.1111\/j.1463-1326.2008.00930.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,1,27]]},"references-count":23,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["10.1111\/j.1463-1326.2008.00930.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1463-1326.2008.00930.x","archive":["Portico"],"relation":{},"ISSN":["1462-8902","1463-1326"],"issn-type":[{"type":"print","value":"1462-8902"},{"type":"electronic","value":"1463-1326"}],"subject":[],"published":{"date-parts":[[2009,1,27]]}}}